Relmada Therapeutics (RLMD) Assets Average (2013 - 2026)

Relmada Therapeutics (RLMD) has 14 years of Assets Average data on file, last reported at $164.7 million in Q1 2026.

• Assets Average for Q1 2026 came in at $164.7 million, up 348.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $164.7 million (up 348.13% YoY), and the FY2025 annual result was $69.9 million, down 2.48% from the prior year.
• Assets Average advanced to $164.7 million in Q1 2026 per RLMD's latest filing, from $54.4 million in the prior quarter.
• Over five years, Assets Average peaked at $224.6 million in Q1 2022 and troughed at $18.0 million in Q3 2025.
• A 5-year average of $111.2 million and a median of $103.4 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average plunged 71.6% in 2025, then surged 348.13% in 2026.
• A 5-year view of Assets Average shows it stood at $170.0 million in 2022, then plunged by 39.21% to $103.4 million in 2023, then sank by 50.87% to $50.8 million in 2024, then advanced by 7.23% to $54.4 million in 2025, then soared by 202.5% to $164.7 million in 2026.
• Business Quant data shows RLMD's Assets Average at $164.7 million in Q1 2026, $54.4 million in Q4 2025, and $18.0 million in Q3 2025.